LumaBio I LP
Open, writing first checksEmerging manager
Open: first sale Jul 2023, per Form D (fund age approximates vintage)
- Vintage
- 2023
- Fund size
- $410M (Form D)
- Stages
- Not stated
- Sectors
- Biotech
- Regions
- Not stated
01 · Thesis
Luma Group is a multistage investment firm focused on biotechnology. It backs teams translating breakthrough science into therapies, diagnostics, and medical devices, combining scientific insight and computation.Inferred from the firm's website
02 · Initial check
$4.1M to $6.83M (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Bill Ryan, Chief Financial Officer
- Joshua Fink, Founder and Managing Member of Adviser
- Thenasap Kahn, Partner and Co-Founder
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideLuma Group is a multistage investment firm focused on biotechnology, combining scientific insight and computation in its investment strategy. It backs teams translating breakthrough science into therapies, diagnostics, and medical devices.
Luma Group is a multistage investment firm focused on biotechnology, bringing together scientific insight and computation to shape both our investment strategy and the companies we back.
https://www.lumagroup.com/
06 · Sources
Last verified: Oct 28, 2026